26 January 2017 - NICE has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.

Epclusa - a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF/VEL; approved as Sovaldi) and the pan-genotypic NS5A inhibitor velpatasvir - is the first all-oral, single tablet regimen cleared for the treatment of adults with genotype 1-6 chronic HCV.

It is also the first single tablet regimen licensed in Europe for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin, which can cause side effects, but physicians may consider the addition of RBV for genotype 3 infected patients with compensated cirrhosis.

Read Pharma Times article